Ecp

Extracorporeal Photopheresis
Synonyms	ECP
Pronounce	N/A
Specialty	N/A
Symptoms
Complications
Onset
Duration
Types
Causes
Risks
Diagnosis
Differential diagnosis
Prevention
Treatment
Medication
Prognosis
Frequency
Deaths	N/A

Extracorporeal Photopheresis (ECP) is a medical treatment that involves the collection of peripheral blood mononuclear cells (PBMCs) from a patient, exposure of these cells to a photosensitizing agent, and subsequent irradiation with ultraviolet A (UVA) light. This process is used primarily in the treatment of various immune-mediated diseases and certain types of cancer.

History

ECP was first developed in the 1980s as a treatment for cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin lymphoma that affects the skin. Since its inception, the use of ECP has expanded to include other conditions such as graft-versus-host disease (GVHD), systemic sclerosis, and organ transplant rejection.

Mechanism of Action

The therapeutic effects of ECP are believed to be mediated through the induction of apoptosis in treated cells and the subsequent modulation of the immune system. The process involves several key steps:

1. Leukapheresis: The patient's blood is drawn and processed through a machine that separates the PBMCs from the rest of the blood components.
2. Photosensitization: The collected cells are mixed with a photosensitizing agent, typically 8-methoxypsoralen (8-MOP).
3. Irradiation: The photosensitized cells are exposed to UVA light, which activates the 8-MOP and induces DNA cross-linking, leading to apoptosis.
4. Reinfusion: The treated cells are reinfused into the patient, where they are thought to exert immunomodulatory effects.

Indications

ECP is indicated for several conditions, including:

• Cutaneous T-cell lymphoma (CTCL)
• Graft-versus-host disease (GVHD)
• Systemic sclerosis
• Organ transplant rejection

Procedure

The ECP procedure typically involves the following steps:

1. Patient Preparation: The patient is prepared for leukapheresis, which may involve the placement of a central venous catheter if peripheral venous access is inadequate. 2. Leukapheresis: Blood is drawn from the patient and processed to separate the PBMCs. 3. Cell Treatment: The PBMCs are treated with 8-MOP and exposed to UVA light. 4. Reinfusion: The treated cells are reinfused into the patient.

Side Effects

ECP is generally well-tolerated, but some patients may experience side effects such as:

• Fatigue
• Nausea
• Fever
• Hypotension

Advantages and Limitations

ECP offers several advantages, including its non-invasive nature and the ability to target specific immune cells. However, it also has limitations, such as the need for specialized equipment and trained personnel.

Future Directions

Research is ongoing to expand the applications of ECP and to better understand its mechanisms of action. Potential future uses include the treatment of autoimmune diseases and chronic inflammatory conditions.

See Also

• Photopheresis
• Immunotherapy
• Leukapheresis

External Links

• [Link to a relevant medical society]
• [Link to a patient information page]

   This article is a medical treatment–related stub. You can help WikiMD by expanding it!